Drug Database
AN

anti-tetanus immunoglobulin (Tetglob)

✓ Approved

Bharat Serums and Vaccines Limited · therapeutic agent

What is anti-tetanus immunoglobulin?

anti-tetanus immunoglobulin is a therapeutic agent developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesTetglob
CompanyBharat Serums and Vaccines Limited
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

anti-tetanus immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedCureus2026-07-17

Generalized Tetanus in an Unvaccinated 52-Year-Old Male Gardener: Diagnostic and Therapeutic Challenges in a Low-Resource Setting.

Qadri Imman I, AlKhawaja Raneem E RE, Mathew Rahul S RS, Khan Israr A IA et al.

Tetanus remains a life-threatening but preventable disease, which continues to manifest in adults lacking sufficient tetanus vaccination and accessibility to tetanus immunoglobulin (TIG). The case discussed is of an unvaccinated 52-year-old Pakistani male patient who developed progressive trismus, difficulty in swallowing, and general spasms following a minor foot wound. The early symptomatology was attributed to psychological stress or heat exhaustion; thus, there was an initial delay in diagnosis. His clinical course was further complicated by the unavailability of TIG, severe autonomic dysfunction, and respiratory compromise requiring prolonged mechanical ventilation and intensive care support. This case is consistent with global patterns, in which unvaccinated adult males with neglected wounds are disproportionately affected, while delayed diagnosis and limited access to immunoglobulin contribute to poorer outcomes. Although intensive care management may help control complications, prolonged recovery with persistent functional impairment is common in the absence of definitive toxin neutralization. This case underscores the need for strengthened tetanus booster vaccination programs, increased clinical awareness of atypical presentations, and resource-sensitive healthcare policies to ensure timely availability of TIG in emergency settings.

PubMedModern rheumatology case reports2026-07-17

Persistent parvovirus B19 infection in an older patient with rheumatoid arthritis receiving immunosuppressive therapy: A case report and literature review.

Oyama Masako M, Yoshida Yusuke Y, Yoshida Tetsumi T, Kobayashi Hiroki H et al.

An 84-year-old man with rheumatoid arthritis undergoing treatment with methotrexate presented with fever, general fatigue, and appetite loss. He had a 3-month history of unexplained normocytic anaemia with reticulocytopenia. Bone marrow examination revealed erythroid hypoplasia with giant pro-erythroblasts, leading to a diagnosis of parvovirus B19 infection. In this case, intravenous immunoglobulin therapy improved the patient's anaemia and systemic symptoms. Six months after the treatment, parvovirus B19 DNA remained detectable using polymerase chain reaction; however, the viral load had markedly decreased, indicating a favourable virological response. Twenty cases of parvovirus B19 infection in older adults (aged ≥65 years) were identified in the literature. Immunocompromised older patients frequently develop persistent parvovirus B19 infections that require treatment with intravenous immunoglobulin therapy, whereas persistent infections are not observed in immunocompetent older individuals. Therefore, this case suggests that clinicians should be aware of persistent parvovirus B19 infection in older immunosuppressed patients who develop unexplained anaemia with reticulocytopenia. Moreover, intravenous immunoglobulin therapy may be considered as an effective therapeutic option for persistent parvovirus B19 infection in immunocompromised patients.

PubMedHandbook of experimental pharmacology2026-07-17

TAAR Immunopharmacology.

Magnesa Anna A, Pacini Andrea A, Rutigliano Grazia G

Trace amine-associated receptors (TAARs) were originally identified as G protein-coupled receptors involved in monoaminergic signaling within the central nervous system. However, accumulating evidence indicates that TAARs, particularly TAAR1 and TAAR2, are also expressed in the immune system, including circulating leukocytes, lymphocytes, macrophages, and microglia. This chapter reviews current evidence regarding TAAR expression, functional pharmacology, and potential translational relevance within the immune system.Expression studies support a predominant TAAR1/TAAR2 pattern across both innate and adaptive immune-cell populations. Functional studies indicate that TAAR signaling can modulate inflammatory responses through chemotaxis, cytokine production, and immunoglobulin secretion. However, these effects are highly context-dependent, preventing a simple classification of TAAR signaling as either pro-inflammatory or anti-inflammatory.The chapter also discusses the emerging role of TAAR signaling in the pathophysiology of diseases, including inflammatory bowel disease, methamphetamine-associated immune dysfunction during HIV infection, multiple sclerosis, Parkinson's disease, fibromyalgia, and hematological malignancies.Despite growing interest in TAAR immunopharmacology, the current evidence remains largely preclinical and methodologically heterogeneous. Major limitations include incomplete protein-level validation, reliance on immortalized cell lines or mixed-cell populations, species-specific pharmacology of available ligands, and limited understanding of physiological trace amine signaling under basal conditions. Further integrative studies will be required to clarify TAAR pathophysiological significance and determine whether TAAR-targeted strategies may have translational relevance in immune-mediated disorders.

PubMedAnnals of diagnostic pathology2026-07-17

From the archives of MD Anderson Cancer Center: Crystal-storing histiocytosis associated with B-cell lymphoma.

Al-Rusan Omar O, Shen Qi Q, Medeiros L Jeffrey LJ

Crystal-storing histiocytosis (CSH) is rare morphologic manifestation of disease histologically characterized by benign histiocytes, usually numerous, filled with cytoplasmic eosinophilic crystals. More than 200 cases have been reported in the literature. In most CSH cases, affected patients also have a plasma cell neoplasm or B-cell lymphoma. We report a 61-year-old man with a remote history of resected colon adenocarcinoma. As part of surveillance imaging he was found to have a 5.5 cm right ureteral/periureteral mass causing hydronephrosis, multi-station lymphadenopathy and splenomegaly. CT-guided biopsy obtained from the mass showed that ≥95% was composed of sheets of histiocytes containing abundant cytoplasmic crystals. The remainder of the specimen was composed of small lymphocytes and plasma cells. Immunohistochemical analysis showed that the lymphocytes were mostly positive for CD5, CD20 and PAX5, and negative for CD3. The plasma cells were positive for monotypic cytoplasmic kappa, CD138 and MUM1/IRF4, and the histiocytes were positive for CD31, CD68, and CD163, with crystals positive for CD68 and MUM1/IRF4. Subsequent bone marrow evaluation with flow cytometry immunophenotypic analysis showed a small monotypic kappa-positive B-cell population positive for CD5, CD19, CD20 and CD23. These findings support the diagnosis of CSH with immunoglobulin crystals associated with B-cell lymphoma. We review the literature on CSH associated with immunoglobulin crystals and discuss the differential diagnosis.

PubMedClinical cancer research : an official journal of the American Association for Cancer Research2026-07-17

Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.

Wilky Breelyn A BA, Julian Katherine A KA, Maleddu Alessandra A, Mailhot Anne C AC et al.

PubMedCancer cell2026-07-17

PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma.

Chen Shuling S, Wang Yuanqi Y, Chen Jingying J, Xie Wenxuan W et al.

The prevailing notion is that effector T cell activation mediates anti-PD-1 efficacy in cancer. Here, we conducted a mechanistic study parallel to our phase 2 trial of perioperative anti-PD-1 therapy in patients with resectable recurrent hepatocellular carcinoma (HCC) (NCT04615143) to study its mechanism of action. Late-recurrence patients present two distinct subtypes characterized by T cell or B cell dominant responses in the tumor microenvironment by dynamic single-cell multi-omics analysis. Clonal antibody repertoire analysis and spatially paired scRNA-seq/BCR-seq reveal somatic hypermutation promoting antibody binding against hepatitis B virus core antigen (HBcAg) within tumor tertiary lymphoid structures (TLSs) in these type B-late recurrence patients. Mechanistically, HBcAg is exported into the extracellular space, triggering local B cell and antibody responses and complement activation. In mice, these high-affinity HBcAg-reactive antibodies lead to complement-mediated antitumor activity with enhanced anti-PD-1 efficacy. Thus, we uncover enhanced anti-virus B cell immunity within the TLS as a mechanism to anti-PD-1 in HCC.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-tetanus immunoglobulin